Results 1 to 10 of about 1,424,912 (261)

Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study

BMC Cancer, 2018
Background There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemotherapy are unknown.
Peng Gao, Xuan-zhang Huang, Yong-xi Song, Jing-xu Sun, Xiao-wan Chen, Yu Sun, Yu-meng Jiang, Zhen-ning Wang   +7 more
doaj   +2 more sources

Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial

BMC Cancer, 2018
Background Some patients develop recurrence after curative resection and adjuvant chemotherapy. S-1, an oral fluoropyrimidine, is one of the standard regimens in adjuvant chemotherapy, and is also used in first-line treatment for advanced/metastatic ...
Seiji Ito, Yasuo Ohashi, Mitsuru Sasako
doaj   +2 more sources

Impact of adjuvant chemotherapy delay on overall survival in early-stage breast cancer: a retrospective analysis [PDF]

Frontiers in Oncology
BackgroundIn Early-Stage Breast Cancer (EBC), there is no clear consensus on the ideal window for initiation of adjuvant chemotherapy from the time of definitive surgery.
Ahmad Alhalabi, Theresa Abdo, María Herrán, Kaylee Sarna, Rami Tfayli, Zeina Nahleh   +5 more
doaj   +2 more sources

Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors [PDF]

The Korean Journal of Internal Medicine, 2022
Background/Aims Adjuvant chemotherapy is the standard of care for resected stage II–IIIA non-small cell lung cancer (NCSLC). The efficacy of adjuvant chemotherapy in stage IB (< 4 cm) NSCLC with high-risk factors is controversial.
Juwhan Choi, Jee Youn Oh, Young Seok Lee, Kyung Hoon Min, Jae Jeong Shim, Sue In Choi, Dong Won Park, Chan Kwon Park, Eun Joo Kang, Hwan Seok Yong, Bong Kyung Shin, Hyun Koo Kim, Sung Yong Lee   +12 more
doaj   +1 more source

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Nature Medicine, 2023
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making ...
D. Kotani, E. Oki, Y. Nakamura, H. Yukami, S. Mishima, H. Bando, H. Shirasu, K. Yamazaki, J. Watanabe, M. Kotaka, K. Hirata, N. Akazawa, K. Kataoka, Shruti Sharma, Vasily N. Aushev, A. Aleshin, T. Misumi, H. Taniguchi, I. Takemasa, T. Kato, Masaki Mori, T. Yoshino   +21 more
semanticscholar   +1 more source

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC

Nature Communications, 2021
Accurately evaluating minimal residual disease (MRD) could facilitate early intervention and personalized adjuvant therapies. Here, using ultradeep targeted next-generation sequencing (NGS), we evaluate the clinical utility of circulating tumor DNA ...
B. Qiu, Wei Guo, Fanshuang Zhang, Fang Lv, Ying Ji, Yue Peng, Xiaoxi Chen, H. Bao, Yang Xu, Y. Shao, F. Tan, Q. Xue, Shugeng Gao, Jie He   +13 more
semanticscholar   +1 more source

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy

JAMA Oncology, 2021
This randomized clinical trial evaluates the effect of postoperative radiotherapy on survival and safety in patients with pIIIA-N2 non–small cell lung cancer after complete resection and adjuvant chemotherapy.
Z. Hui, Y. Men, Chen Hu, Jingjing Kang, Xin Sun, N. Bi, Zongmei Zhou, Jun Liang, J. Lv, Q. Feng, Z. Xiao, Dong-fu Chen, Yan Wang, Junling Li, Jie Wang, Shugeng Gao, Luhua Wang, Jie He   +17 more
semanticscholar   +1 more source

Differences in prognosis and underuse of adjuvant chemotherapy between elderly and non‐elderly patients in stage III colorectal cancer

Annals of Gastroenterological Surgery, 2023
Aim We aimed to clarify the use of adjuvant chemotherapy and the prognosis of elderly colorectal cancer patients compared with non‐elderly patients, and the usefulness of sarcopenia as an indicator for the introduction and completion of adjuvant ...
Takuya Shiraishi, Hiroomi Ogawa, Ikuma Shioi, Naoya Ozawa, Katsuya Osone, Takuhisa Okada, Makoto Sohda, Ken Shirabe, Hiroshi Saeki   +8 more
doaj   +1 more source

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Journal of Clinical Oncology, 2022
PURPOSE To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer.
F. André, Nofisat Ismaila, K. Allison, W. Barlow, D. Collyar, S. Damodaran, N. L. Henry, K. Jhaveri, K. Kalinsky, N. Kuderer, A. Litvak, E. Mayer, L. Pusztai, R. Raab, A. Wolff, V. Stearns   +15 more
semanticscholar   +1 more source

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy

JAMA Network Open, 2022
Key Points Question Is adjuvant chemotherapy associated with a survival benefit for patients with locally advanced gastric cancer who underwent curative-intent gastrectomy after neoadjuvant chemotherapy? Findings In this cohort study of 462 patients with
Jian-Xian Lin, Yi-hui Tang, Guan-Jie Lin, Yu-bin Ma, J. Desiderio, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, L. Cao, Mi Lin, R. Tu, C. Zheng, A. Parisi, M. Truty, Chang-ming Huang   +16 more
semanticscholar   +1 more source